BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2868783/0/en/BioXcel-Therapeutics-Announces-Late-Breaking-Abstract-on-Preliminary-Findings-from-Phase-2-Investigator-Sponsored-Trial-of-BXCL701-and-KEYTRUDA-in-Metastatic-Pancreatic-Ductal-Aden.html

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET

Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.